Global Bioartificial Kidney Market By Clinical Trial (Pre-Clinical, Phase I Clinical Trial, Others), By Application (Short-Term Solution Of Renal Dialysis, Longer-Term Of A Living Kidney Transplant, Polycystic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS), Others), By End-User (Hospital, Organ Transplant Centers, Research Institutes, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1081 | Category : Healthcare | Published Date : March, 2022 | Pages : 402 | Format :PDF

Industry Trends

Bioartificial kidneys are made up of a typical hemofilter connected in series with a bioreactor unit containing renal epithelial cells. The renal tubule epithelial cells should perform transport, metabolic, endocrinologic, and immunomodulatory tasks. The bioartificial kidney filters waste by convection, which uses the body's natural blood pressure to separate blood cells, proteins, and other major components from small toxins and waste particles that can fit through the hemofilter's pores. The integration of the silicon nano membrane hemofilter and the bioreactor with human kidney cells combines the best of both concepts in a bio hybrid approach, resulting in the "bioartificial" kidney, which contains both biological and entirely synthetic components. The increased incidence of renal failure and a long waiting list for kidney transplants are major factors that are expected to drive the growth of the global bioartificial kidney market in the near future.

The growing number of chronic kidney disease patients is one of the significant factors for the growth of the market. According to data from the Centers for Disease Control and Prevention, chronic kidney disease affects more than 1 in 7, or 15% of U.S. adults, or 37 million individuals, in the United States. As many as 9 out of 10 persons with CKD are unaware of their condition, and approximately 2 out of 5 adults with severe CKD are unaware of their condition. Moreover, the federal government, which is the principle payer for such patients' medical care, is pushing agencies to accelerate the development of technologies that could improve care. The Kidney Project has been chosen to participate in two FDA-sponsored programs, the Innovation Pathway 2.0 and the Expedited Access Pathway, both of which aim to reduce the time it takes to bring safe and effective technologies to the market. However, reimbursement issues, as well as the risks and problems associated with dialysis treatment, are hindering the growth of global bioartificial kidney market.

The novel coronavirus disease 2019 (COVID-19) has a high mortality rate among older adults and people suffering from chronic conditions such as chronic kidney disease (CKD). Despite the fact that numerous studies have lately indicated several techniques for the management of COVID-19 in CKD, its impact on individuals with renal illnesses remains the greatest challenge globally. Furthermore, patients with end-stage kidney illness were considered to be a largely susceptible group for COVID-19, with an infection prevalence of 16%. The prevalence of CKD in COVID-19 individuals has been estimated to be between 0.09% and 47.05%. Furthermore, rising promise of innovation in artificial kidney technology promises new potential for industry participants in the bioartificial kidney market to gain momentum.

In terms of revenue, the bioartificial kidney market is projected to grow at a CAGR of 36.87% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

Global Bioartificial Kidney Market Revenue & Forecast, (US$ Million), 2015 – 2030

global bioartificial kidney market

Clinical Trial Outlook:

Based on clinical trial, the global bioartificial kidney market has been primarily segmented into pre-clinical, phase I clinical trial, and others. Key players from the market are in the pre-clinical stage such as the "bioartificial kidney" invented by the laboratory of H. David Humes, MD is a two-part device consisting of a blood circuit in which a commercial hemofilter is guided by a novel "Renal Assist Device" (RAD) containing living human cells. The FDA has approved a phase I clinical trial of the bioartificial kidney for the treatment of critically ill patients that are already in the intensive care unit (ICU) and are receiving Continuous Venovenous Hemofiltration (CVVH) for acute renal failure.

Application Outlook:

Based on application, the global bioartificial kidney market has been segmented into short-term solution of renal dialysis, longer-term of a living kidney transplant, polycystic kidney disease, focal segmental glomerulosclerosis (FSGS), and others. Scientists are working on developing an artificial kidney that can replicate the function of real organs and eliminate the need for dialysis. The University of California, San Francisco (UCSF) is developing an implantable artificial kidney that can directly replicate the functions of real kidneys. One of the most important applications of the bioartificial kidney is the ability to extend the life of a living kidney transplant.

End-User Outlook:

Based on end-user, the global bioartificial kidney market has been segmented into hospitals, organ transplant centers, research institutes, and others. A bioartificial kidney is in the developing phase, research centers and institutes are primarily focused on the development of this kidney in order to help patients live longer lives. Also, increasing research and development activities have contributed to market growth in recent decades, which is accounting for the major market share.

Region Outlook:

Based on regions, North America accounted for the largest market share in the bioartificial kidney market, owing to the increased adoption of advanced technologies and the presence of major players in the major economies such as the United States, Canada, and Mexico. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), more than 661,000 people in the United States had kidney failure in 2017, with 468,000 on dialysis. Furthermore, the bioartificial kidney market is expected to rise due to an increase in R&D activities in the healthcare sector to develop novel bioartificial kidneys.

Competitive Landscape Outlook:

The report provides both, qualitative and quantitative research of the global bioartificial kidney market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.

Some of the players operating in the bioartificial kidney market are

  • AWAK Technologies
  • Blood Purification Technologies Inc.
  • Dutch Kidney Foundation
  • UCSF
  • Other Market Participants

Global Bioartificial Kidney Market

  • By Clinical Trial

    • Pre-Clinical
    • Phase I clinical trial
    • Others
  • By Application

    • Short-term solution of renal dialysis
    • Longer-term of a living kidney transplant
    • Polycystic Kidney Disease
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Others
  • By End-User

    • Hospital
    • Organ Transplant Centers
    • Research Institutes
    • Others
  • By Region

    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Table of Contents


 

1.    Market Scope

1.1.   Market Segmentation

1.2.   Years Considered

1.2.1.   Forecast Years: 2022 – 2030

2.    Key Target Audiences

3.    Research Methodology

3.1.   Primary Research

3.1.1.   Research Questionnaire

3.1.2.   Global Percentage Breakdown

3.1.3.   Primary Interviews: Key Opinion Leaders (KOLs)

3.2.   Secondary Research

3.2.1.   Paid Databases

3.2.2.   Secondary Sources

3.3.   Market Size Estimates

3.3.1.   Top-Down Approach

3.3.2.   Bottom-Up Approach

3.4.   Data Triangulation Methodology

3.5.   Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Bioartificial Kidney Market

6.    Market Synopsis: Bioartificial Kidney Market

7.    Bioartificial Kidney Market Analysis: Qualitative Perspective

7.1.   Introduction

7.1.1.   Product Definition

7.1.2.   Industry Development

7.2.   Market Dynamics

7.2.1.   Drivers

7.2.2.   Restraints

7.2.3.   Opportunities

7.2.4.   Challenges

7.3.   Trends in Bioartificial Kidney Market

7.4.   Market Determinants Radar Chart

7.5.   Macro-Economic and Micro-Economic Indicators: Bioartificial Kidney Market

7.6.   Industry Gross Margin Overview

7.7.   Porter’s Five Force Analysis

7.8.   Impact of Covid-19 on Bioartificial Kidney Market

8.    Global Bioartificial Kidney Market Analysis and Forecasts, 2022 – 2030

8.1.   Overview

8.1.1.   Global Bioartificial Kidney Market Revenue (US$ Mn)

8.2.   Global Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

8.2.1.   Pre-Clinical

8.2.1.1.    Definition

8.2.1.2.    Market Forecast, 2022 - 2030

8.2.1.3.    Compound Annual Growth Rate (CAGR)

8.2.1.4.    Regional Bifurcation

8.2.1.4.1.    North America

8.2.1.4.1.1.  Market Forecast, 2022 - 2030

8.2.1.4.2.    Europe

8.2.1.4.2.1.  Market Forecast, 2022 - 2030

8.2.1.4.3.    Asia Pacific

8.2.1.4.3.1.  Market Forecast, 2022 - 2030

8.2.1.4.4.    Middle East and Africa

8.2.1.4.4.1.  Market Forecast, 2022 - 2030

8.2.1.4.5.    Latin America

8.2.1.4.5.1.  Market Forecast, 2022 - 2030

8.2.2.                         Phase I clinical trial

8.2.2.1.    Definition

8.2.2.2.    Market Forecast, 2022 - 2030

8.2.2.3.    Compound Annual Growth Rate (CAGR)

8.2.2.4.    Regional Bifurcation

8.2.2.4.1.    North America

8.2.2.4.1.1.  Market Forecast, 2022 - 2030

8.2.2.4.2.    Europe

8.2.2.4.2.1.  Market Forecast, 2022 - 2030

8.2.2.4.3.    Asia Pacific

8.2.2.4.3.1.  Market Forecast, 2022 - 2030

8.2.2.4.4.    Middle East and Africa

8.2.2.4.4.1.  Market Forecast, 2022 - 2030

8.2.2.4.5.    Latin America

8.2.2.4.5.1.  Market Forecast, 2022 - 2030

8.2.3.   Others

8.2.3.1.    Definition

8.2.3.2.    Market Forecast, 2022 - 2030

8.2.3.3.    Compound Annual Growth Rate (CAGR)

8.2.3.4.    Regional Bifurcation

8.2.3.4.1.    North America

8.2.3.4.1.1.  Market Forecast, 2022 - 2030

8.2.3.4.2.    Europe

8.2.3.4.2.1.  Market Forecast, 2022 - 2030

8.2.3.4.3.    Asia Pacific

8.2.3.4.3.1.  Market Forecast, 2022 - 2030

8.2.3.4.4.    Middle East and Africa

8.2.3.4.4.1.  Market Forecast, 2022 - 2030

8.2.3.4.5.    Latin America

8.2.3.4.5.1.  Market Forecast, 2022 - 2030

8.3.   Key Segment for Channeling Investments

8.3.1.   By Clinical Trial

9.    Global Bioartificial Kidney Market Analysis and Forecasts, 2022 – 2030

9.1.   Overview

9.2.   Global Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

9.2.1.   Short-term solution of renal dialysis

9.2.1.1.    Definition

9.2.1.2.    Market Forecast, 2022 - 2030

9.2.1.3.    Compound Annual Growth Rate (CAGR)

9.2.1.4.    Regional Bifurcation

9.2.1.4.1.    North America

9.2.1.4.1.1.  Market Forecast, 2022 - 2030

9.2.1.4.2.    Europe

9.2.1.4.2.1.  Market Forecast, 2022 - 2030

9.2.1.4.3.    Asia Pacific

9.2.1.4.3.1.  Market Forecast, 2022 - 2030

9.2.1.4.4.    Middle East and Africa

9.2.1.4.4.1.  Market Forecast, 2022 - 2030

9.2.1.4.5.    Latin America

9.2.1.4.5.1.  Market Forecast, 2022 - 2030

9.2.2.   Longer-term of a living kidney transplant

9.2.2.1.    Definition

9.2.2.2.    Market Forecast, 2022 - 2030

9.2.2.3.    Compound Annual Growth Rate (CAGR)

9.2.2.4.    Regional Bifurcation

9.2.2.4.1.    North America

9.2.2.4.1.1.  Market Forecast, 2022 - 2030

9.2.2.4.2.    Europe

9.2.2.4.2.1.  Market Forecast, 2022 - 2030

9.2.2.4.3.    Asia Pacific

9.2.2.4.3.1.  Market Forecast, 2022 - 2030

9.2.2.4.4.    Middle East and Africa

9.2.2.4.4.1.  Market Forecast, 2022 - 2030

9.2.2.4.5.    Latin America

9.2.2.4.5.1.  Market Forecast, 2022 - 2030

9.2.3.   Polycystic Kidney Disease

9.2.3.1.    Definition

9.2.3.2.    Market Forecast, 2022 - 2030

9.2.3.3.    Compound Annual Growth Rate (CAGR)

9.2.3.4.    Regional Bifurcation

9.2.3.4.1.    North America

9.2.3.4.1.1.  Market Forecast, 2022 - 2030

9.2.3.4.2.    Europe

9.2.3.4.2.1.  Market Forecast, 2022 - 2030

9.2.3.4.3.    Asia Pacific

9.2.3.4.3.1.  Market Forecast, 2022 - 2030

9.2.3.4.4.    Middle East and Africa

9.2.3.4.4.1.  Market Forecast, 2022 - 2030

9.2.3.4.5.    Latin America

9.2.3.4.5.1.  Market Forecast, 2022 - 2030

9.2.4.   Focal Segmental Glomerulosclerosis (FSGS)

9.2.4.1.    Definition

9.2.4.2.    Market Forecast, 2022 - 2030

9.2.4.3.    Compound Annual Growth Rate (CAGR)

9.2.4.4.    Regional Bifurcation

9.2.4.4.1.    North America

9.2.4.4.1.1.  Market Forecast, 2022 - 2030

9.2.4.4.2.    Europe

9.2.4.4.2.1.  Market Forecast, 2022 - 2030

9.2.4.4.3.    Asia Pacific

9.2.4.4.3.1.  Market Forecast, 2022 - 2030

9.2.4.4.4.    Middle East and Africa

9.2.4.4.4.1.  Market Forecast, 2022 - 2030

9.2.4.4.5.    Latin America

9.2.4.4.5.1.  Market Forecast, 2022 - 2030

9.2.5.   Others

9.2.5.1.    Definition

9.2.5.2.    Market Forecast, 2022 - 2030

9.2.5.3.    Compound Annual Growth Rate (CAGR)

9.2.5.4.    Regional Bifurcation

9.2.5.4.1.    North America

9.2.5.4.1.1.  Market Forecast, 2022 - 2030

9.2.5.4.2.    Europe

9.2.5.4.2.1.  Market Forecast, 2022 - 2030

9.2.5.4.3.    Asia Pacific

9.2.5.4.3.1.  Market Forecast, 2022 - 2030

9.2.5.4.4.    Middle East and Africa

9.2.5.4.4.1.  Market Forecast, 2022 - 2030

9.2.5.4.5.    Latin America

9.2.5.4.5.1.  Market Forecast, 2022 - 2030

9.3.   Key Segment for Channeling Investments

9.3.1.   By Application

10.  Global Bioartificial Kidney Market Analysis and Forecasts, 2022 – 2030

10.1. Overview

10.2. Global Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

10.2.1. Hospital

10.2.1.1.  Definition

10.2.1.2.  Market Forecast, 2022 - 2030

10.2.1.3.  Compound Annual Growth Rate (CAGR)

10.2.1.4.  Regional Bifurcation

10.2.1.4.1.  North America

10.2.1.4.1.1.  Market Forecast, 2022 - 2030

10.2.1.4.2.  Europe

10.2.1.4.2.1.  Market Forecast, 2022 - 2030

10.2.1.4.3.  Asia Pacific

10.2.1.4.3.1.  Market Forecast, 2022 - 2030 10.2.1.4.4. Middle East and Africa

10.2.1.4.4.1. Market Forecast, 2022 - 2030

10.2.1.4.5.  Latin America

10.2.1.4.5.1.  Market Forecast, 2022 - 2030

10.2.2. Organ Transplant Centers

10.2.2.1.  Definition

10.2.2.2.  Market Forecast, 2022 - 2030

10.2.2.3.  Compound Annual Growth Rate (CAGR)

10.2.2.4.  Regional Bifurcation

10.2.2.4.1.  North America

10.2.2.4.1.1.  Market Forecast, 2022 - 2030

10.2.2.4.2.  Europe

10.2.2.4.2.1.  Market Forecast, 2022 - 2030

10.2.2.4.3.  Asia Pacific

10.2.2.4.3.1.  Market Forecast, 2022 - 2030 10.2.2.4.4. Middle East and Africa

10.2.2.4.4.1. Market Forecast, 2022 - 2030

10.2.2.4.5.  Latin America

10.2.2.4.5.1.  Market Forecast, 2022 - 2030

10.2.3.                      Research Institutes

10.2.3.1.  Definition

10.2.3.2.  Market Forecast, 2022 - 2030

10.2.3.3.  Compound Annual Growth Rate (CAGR)

10.2.3.4.  Regional Bifurcation

10.2.3.4.1.  North America

10.2.3.4.1.1.  Market Forecast, 2022 - 2030

10.2.3.4.2.  Europe

10.2.3.4.2.1.  Market Forecast, 2022 - 2030

10.2.3.4.3.  Asia Pacific

10.2.3.4.3.1.  Market Forecast, 2022 - 2030 10.2.3.4.4. Middle East and Africa

10.2.3.4.4.1. Market Forecast, 2022 - 2030

10.2.3.4.5.  Latin America

10.2.3.4.5.1.  Market Forecast, 2022 - 2030

10.2.4. Others

10.2.4.1.  Definition

10.2.4.2.  Market Forecast, 2022 - 2030

10.2.4.3.  Compound Annual Growth Rate (CAGR)

10.2.4.4.  Regional Bifurcation

10.2.4.4.1.  North America

10.2.4.4.1.1.  Market Forecast, 2022 - 2030

10.2.4.4.2.  Europe

10.2.4.4.2.1.  Market Forecast, 2022 - 2030

10.2.4.4.3.  Asia Pacific

10.2.4.4.3.1.  Market Forecast, 2022 - 2030 10.2.4.4.4. Middle East and Africa

10.2.4.4.4.1. Market Forecast, 2022 - 2030

10.2.4.4.5.  Latin America

10.2.4.4.5.1.  Market Forecast, 2022 - 2030

10.3. Key Segment for Channeling Investments

10.3.1. By End User

11.  North America Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030

11.1. Overview

11.1.1. North America Bioartificial Kidney Market Revenue (US$ Mn)

11.2. North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

11.2.1. Pre-Clinical

11.2.2. Phase I clinical trial

11.2.3. Others

11.3. North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Short-term solution of renal dialysis

11.3.2. Longer-term of a living kidney transplant

11.3.3. Polycystic Kidney Disease

11.3.4. Focal Segmental Glomerulosclerosis (FSGS)

11.3.5. Others

11.4. North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

11.4.1. Hospital

11.4.2. Organ Transplant Centers

11.4.3. Research Institutes

11.4.4. Others

11.5. North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

11.5.1. U.S

11.5.1.1.  U.S Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

11.5.1.1.1.  Pre-Clinical 11.5.1.1.2. Phase I clinical trial

11.5.1.1.3. Others

11.5.1.2.  U.S Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

11.5.1.2.1.  Short-term solution of renal dialysis 11.5.1.2.2. Longer-term of a living kidney transplant 11.5.1.2.3. Polycystic Kidney Disease

11.5.1.2.4. Focal Segmental Glomerulosclerosis (FSGS) 11.5.1.2.5. Others

11.5.1.3.  U.S Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

11.5.1.3.1.  Hospital

11.5.1.3.2.  Organ Transplant Centers 11.5.1.3.3. Research Institutes

11.5.1.3.4. Others

11.5.2.  Canada

11.5.2.1.  Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

11.5.2.1.1.  Pre-Clinical 11.5.2.1.2. Phase I clinical trial 11.5.2.1.3. Others

11.5.2.2.  Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

11.5.2.2.1.  Short-term solution of renal dialysis 11.5.2.2.2. Longer-term of a living kidney transplant 11.5.2.2.3. Polycystic Kidney Disease

11.5.2.2.4. Focal Segmental Glomerulosclerosis (FSGS) 11.5.2.2.5. Others

11.5.2.3.  Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

11.5.2.3.1.  Hospital

11.5.2.3.2.  Organ Transplant Centers 11.5.2.3.3. Research Institutes

11.5.2.3.4. Others

11.5.3.  Mexico

11.5.3.1.  Mexico Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

11.5.3.1.1.  Pre-Clinical 11.5.3.1.2. Phase I clinical trial

11.5.3.1.3. Others

11.5.3.2.  Mexico Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

11.5.3.2.1.  Short-term solution of renal dialysis 11.5.3.2.2. Longer-term of a living kidney transplant 11.5.3.2.3. Polycystic Kidney Disease

11.5.3.2.4. Focal Segmental Glomerulosclerosis (FSGS) 11.5.3.2.5. Others

11.5.3.3.  Mexico Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

11.5.3.3.1.  Hospital

11.5.3.3.2.  Organ Transplant Centers 11.5.3.3.3. Research Institutes

11.5.3.3.4. Others

11.5.4.  Rest of North America

11.5.4.1.  Rest of North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

11.5.4.1.1.  Pre-Clinical 11.5.4.1.2. Phase I clinical trial 11.5.4.1.3. Others

11.5.4.2.  Rest of North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

11.5.4.2.1.  Short-term solution of renal dialysis 11.5.4.2.2. Longer-term of a living kidney transplant 11.5.4.2.3. Polycystic Kidney Disease

11.5.4.2.4. Focal Segmental Glomerulosclerosis (FSGS) 11.5.4.2.5. Others

11.5.4.3.  Rest of North America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

11.5.4.3.1.  Hospital

11.5.4.3.2.  Organ Transplant Centers 11.5.4.3.3. Research Institutes

11.5.4.3.4. Others

11.6. Key Segment for Channeling Investments

11.6.1. By Country

11.6.2. By Clinical Trial

11.6.3. By Application

11.6.4. By End User

12.  Europe Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.1.1. Europe Bioartificial Kidney Market Revenue (US$ Mn)

12.2. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.2.1. Pre-Clinical

12.2.2. Phase I clinical trial

12.2.3. Others

12.3. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.3.1. Short-term solution of renal dialysis

12.3.2. Longer-term of a living kidney transplant

12.3.3. Polycystic Kidney Disease

12.3.4. Focal Segmental Glomerulosclerosis (FSGS)

12.3.5. Others

12.4. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.4.1. Hospital

12.4.2. Organ Transplant Centers

12.4.3. Research Institutes

12.4.4. Others

12.5. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

12.5.1. France

12.5.1.1.  France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.1.1.1.  Pre-Clinical 12.5.1.1.2. Phase I clinical trial 12.5.1.1.3. Others

12.5.1.2.  France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.1.2.1.  Short-term solution of renal dialysis 12.5.1.2.2. Longer-term of a living kidney transplant 12.5.1.2.3. Polycystic Kidney Disease

12.5.1.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.1.2.5. Others

12.5.1.3.  France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.1.3.1.  Hospital

12.5.1.3.2.  Organ Transplant Centers 12.5.1.3.3. Research Institutes

12.5.1.3.4. Others

12.5.2. The UK

12.5.2.1.  The UK Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.2.1.1.  Pre-Clinical 12.5.2.1.2. Phase I clinical trial 12.5.2.1.3. Others

12.5.2.2.  The UK Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.2.2.1.  Short-term solution of renal dialysis 12.5.2.2.2. Longer-term of a living kidney transplant 12.5.2.2.3. Polycystic Kidney Disease

12.5.2.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.2.2.5. Others

12.5.2.3.  The UK Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.2.3.1.  Hospital

12.5.2.3.2.  Organ Transplant Centers 12.5.2.3.3. Research Institutes

12.5.2.3.4. Others

12.5.3. Spain

12.5.3.1.  Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.3.1.1.  Pre-Clinical 12.5.3.1.2. Phase I clinical trial 12.5.3.1.3. Others

12.5.3.2.  Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.3.2.1.  Short-term solution of renal dialysis 12.5.3.2.2. Longer-term of a living kidney transplant 12.5.3.2.3. Polycystic Kidney Disease

12.5.3.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.3.2.5. Others

12.5.3.3.  Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.3.3.1.  Hospital

12.5.3.3.2.  Organ Transplant Centers 12.5.3.3.3. Research Institutes

12.5.3.3.4. Others

12.5.4. Germany

12.5.4.1.  Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.4.1.1.  Pre-Clinical 12.5.4.1.2. Phase I clinical trial 12.5.4.1.3. Others

12.5.4.2.  Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.4.2.1.  Short-term solution of renal dialysis 12.5.4.2.2. Longer-term of a living kidney transplant 12.5.4.2.3. Polycystic Kidney Disease

12.5.4.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.4.2.5. Others

12.5.4.3.  Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.4.3.1.  Hospital

12.5.4.3.2.  Organ Transplant Centers 12.5.4.3.3. Research Institutes

12.5.4.3.4. Others

12.5.5. Italy

12.5.5.1.  Italy Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.5.1.1.  Pre-Clinical 12.5.5.1.2. Phase I clinical trial 12.5.5.1.3. Others

12.5.5.2.  Italy Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.5.2.1.  Short-term solution of renal dialysis 12.5.5.2.2. Longer-term of a living kidney transplant 12.5.5.2.3. Polycystic Kidney Disease

12.5.5.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.5.2.5. Others

12.5.5.3.  Italy Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.5.3.1.  Hospital

12.5.5.3.2.  Organ Transplant Centers 12.5.5.3.3. Research Institutes

12.5.5.3.4. Others

12.5.6. Nordic Countries

12.5.6.1.  Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.6.1.1.  Pre-Clinical 12.5.6.1.2. Phase I clinical trial 12.5.6.1.3. Others

12.5.6.2.  Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.6.2.1.  Short-term solution of renal dialysis 12.5.6.2.2. Longer-term of a living kidney transplant 12.5.6.2.3. Polycystic Kidney Disease

12.5.6.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.6.2.5. Others

12.5.6.3.  Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.6.3.1.  Hospital

12.5.6.3.2.  Organ Transplant Centers 12.5.6.3.3. Research Institutes

12.5.6.3.4. Others

12.5.6.4.  Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

12.5.6.4.1.  Denmark

12.5.6.4.2.  Finland

12.5.6.4.3.  Iceland

12.5.6.4.4.  Sweden

12.5.6.4.5.  Norway

12.5.7. Benelux Union

12.5.7.1.  Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.7.1.1.  Pre-Clinical 12.5.7.1.2. Phase I clinical trial 12.5.7.1.3. Others

12.5.7.2.  Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.7.2.1.  Short-term solution of renal dialysis 12.5.7.2.2. Longer-term of a living kidney transplant 12.5.7.2.3. Polycystic Kidney Disease

12.5.7.2.4.  Focal Segmental Glomerulosclerosis (FSGS)

12.5.7.2.5.  Others

12.5.7.3.  Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.7.3.1.  Hospital

12.5.7.3.2.  Organ Transplant Centers 12.5.7.3.3. Research Institutes

12.5.7.3.4. Others

12.5.7.4.  Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

12.5.7.4.1.  Belgium

12.5.7.4.2.  The Netherlands

12.5.7.4.3.  Luxembourg

12.5.8. Rest of Europe

12.5.8.1.  Rest of Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

12.5.8.1.1.  Pre-Clinical 12.5.8.1.2. Phase I clinical trial 12.5.8.1.3. Others

12.5.8.2.  Rest of Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

12.5.8.2.1.  Short-term solution of renal dialysis 12.5.8.2.2. Longer-term of a living kidney transplant 12.5.8.2.3. Polycystic Kidney Disease

12.5.8.2.4. Focal Segmental Glomerulosclerosis (FSGS) 12.5.8.2.5. Others

12.5.8.3.  Rest of Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

12.5.8.3.1.  Hospital

12.5.8.3.2.  Organ Transplant Centers 12.5.8.3.3. Research Institutes

12.5.8.3.4. Others

12.6. Key Segment for Channeling Investments

12.6.1. By Country

12.6.2. By Clinical Trial

12.6.3. By Application

12.6.4. By End User

13.  Asia Pacific Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn)

13.2. Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.2.1. Pre-Clinical

13.2.2. Phase I clinical trial

13.2.3. Others

13.3. Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.3.1. Short-term solution of renal dialysis

13.3.2. Longer-term of a living kidney transplant

13.3.3. Polycystic Kidney Disease

13.3.4. Focal Segmental Glomerulosclerosis (FSGS)

13.3.5. Others

13.4. Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.4.1. Hospital

13.4.2. Organ Transplant Centers

13.4.3. Research Institutes

13.4.4. Others

13.5. Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

13.5.1. China

13.5.1.1.  China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.1.1.1.  Pre-Clinical 13.5.1.1.2. Phase I clinical trial 13.5.1.1.3. Others

13.5.1.2.  China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.1.2.1.  Short-term solution of renal dialysis 13.5.1.2.2. Longer-term of a living kidney transplant 13.5.1.2.3. Polycystic Kidney Disease

13.5.1.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.1.2.5. Others

13.5.1.3.  China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.1.3.1.  Hospital

13.5.1.3.2.  Organ Transplant Centers 13.5.1.3.3. Research Institutes

13.5.1.3.4. Others

13.5.2. Japan

13.5.2.1.  Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.2.1.1.  Pre-Clinical 13.5.2.1.2. Phase I clinical trial 13.5.2.1.3. Others

13.5.2.2.  Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.2.2.1.  Short-term solution of renal dialysis 13.5.2.2.2. Longer-term of a living kidney transplant 13.5.2.2.3. Polycystic Kidney Disease

13.5.2.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.2.2.5. Others

13.5.2.3.  Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.2.3.1.  Hospital

13.5.2.3.2.  Organ Transplant Centers 13.5.2.3.3. Research Institutes

13.5.2.3.4. Others

13.5.3. India

13.5.3.1.  India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.3.1.1.  Pre-Clinical 13.5.3.1.2. Phase I clinical trial 13.5.3.1.3. Others

13.5.3.2.  India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.3.2.1.  Short-term solution of renal dialysis 13.5.3.2.2. Longer-term of a living kidney transplant 13.5.3.2.3. Polycystic Kidney Disease

13.5.3.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.3.2.5. Others

13.5.3.3.  India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.3.3.1.  Hospital

13.5.3.3.2.  Organ Transplant Centers 13.5.3.3.3. Research Institutes

13.5.3.3.4. Others

13.5.4. New Zealand

13.5.4.1.  New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.4.1.1.  Pre-Clinical 13.5.4.1.2. Phase I clinical trial 13.5.4.1.3. Others

13.5.4.2.  New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.4.2.1.  Short-term solution of renal dialysis 13.5.4.2.2. Longer-term of a living kidney transplant 13.5.4.2.3. Polycystic Kidney Disease

13.5.4.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.4.2.5. Others

13.5.4.3.  New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.4.3.1.  Hospital

13.5.4.3.2.  Organ Transplant Centers 13.5.4.3.3. Research Institutes

13.5.4.3.4. Others

13.5.5. Australia

13.5.5.1.  Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.5.1.1.  Pre-Clinical 13.5.5.1.2. Phase I clinical trial 13.5.5.1.3. Others

13.5.5.2.  Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.5.2.1.  Short-term solution of renal dialysis 13.5.5.2.2. Longer-term of a living kidney transplant 13.5.5.2.3. Polycystic Kidney Disease

13.5.5.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.5.2.5. Others

13.5.5.3.  Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.5.3.1.  Hospital

13.5.5.3.2.  Organ Transplant Centers 13.5.5.3.3. Research Institutes

13.5.5.3.4. Others

13.5.6. South Korea

13.5.6.1.  South Korea Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.6.1.1.  Pre-Clinical 13.5.6.1.2. Phase I clinical trial 13.5.6.1.3. Others

13.5.6.2.  South Korea Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.6.2.1.  Short-term solution of renal dialysis 13.5.6.2.2. Longer-term of a living kidney transplant 13.5.6.2.3. Polycystic Kidney Disease

13.5.6.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.6.2.5. Others

13.5.6.3.  South Korea Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.6.3.1.  Hospital

13.5.6.3.2.  Organ Transplant Centers 13.5.6.3.3. Research Institutes

13.5.6.3.4. Others

13.5.7. Southeast Asia

13.5.7.1.  Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.7.1.1.  Pre-Clinical 13.5.7.1.2. Phase I clinical trial 13.5.7.1.3. Others

13.5.7.2.  Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.7.2.1.  Short-term solution of renal dialysis 13.5.7.2.2. Longer-term of a living kidney transplant 13.5.7.2.3. Polycystic Kidney Disease

13.5.7.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.7.2.5. Others

13.5.7.3.  Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.7.3.1.  Hospital

13.5.7.3.2.  Organ Transplant Centers 13.5.7.3.3. Research Institutes

13.5.7.3.4. Others

13.5.7.4.  Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

13.5.7.4.1.  Indonesia

13.5.7.4.2.  Thailand

13.5.7.4.3.  Malaysia

13.5.7.4.4.  Singapore

13.5.7.4.5.  Rest of Southeast Asia

13.5.8. Rest of Asia Pacific

13.5.8.1.  Rest of Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

13.5.8.1.1.  Pre-Clinical 13.5.8.1.2. Phase I clinical trial 13.5.8.1.3. Others

13.5.8.2.  Rest of Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

13.5.8.2.1.  Short-term solution of renal dialysis 13.5.8.2.2. Longer-term of a living kidney transplant 13.5.8.2.3. Polycystic Kidney Disease

13.5.8.2.4. Focal Segmental Glomerulosclerosis (FSGS) 13.5.8.2.5. Others

13.5.8.3.  Rest of Asia Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

13.5.8.3.1.  Hospital

13.5.8.3.2.  Organ Transplant Centers 13.5.8.3.3. Research Institutes

13.5.8.3.4. Others

13.6. Key Segment for Channeling Investments

13.6.1. By Country

13.6.2. By Clinical Trial

13.6.3. By Application

13.6.4. By End User

14.  Middle East and Africa Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn)

14.2. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.2.1. Pre-Clinical

14.2.2. Phase I clinical trial

14.2.3. Others

14.3. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.3.1. Short-term solution of renal dialysis

14.3.2. Longer-term of a living kidney transplant

14.3.3. Polycystic Kidney Disease

14.3.4. Focal Segmental Glomerulosclerosis (FSGS)

14.3.5. Others

14.4. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.4.1. Hospital

14.4.2. Organ Transplant Centers

14.4.3. Research Institutes

14.4.4. Others

14.5. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

14.5.1. Saudi Arabia

14.5.1.1.  Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.1.1.1.  Pre-Clinical 14.5.1.1.2. Phase I clinical trial 14.5.1.1.3. Others

14.5.1.2.  Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.1.2.1.  Short-term solution of renal dialysis 14.5.1.2.2. Longer-term of a living kidney transplant 14.5.1.2.3. Polycystic Kidney Disease

14.5.1.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.1.2.5. Others

14.5.1.3.  Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.1.3.1.  Hospital

14.5.1.3.2.  Organ Transplant Centers 14.5.1.3.3. Research Institutes

14.5.1.3.4. Others

14.5.2. UAE

14.5.2.1.  UAE Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.2.1.1.  Pre-Clinical 14.5.2.1.2. Phase I clinical trial

14.5.2.1.3. Others

14.5.2.2.  UAE Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.2.2.1.  Short-term solution of renal dialysis 14.5.2.2.2. Longer-term of a living kidney transplant 14.5.2.2.3. Polycystic Kidney Disease

14.5.2.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.2.2.5. Others

14.5.2.3.  UAE Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.2.3.1.  Hospital

14.5.2.3.2.  Organ Transplant Centers 14.5.2.3.3. Research Institutes

14.5.2.3.4. Others

14.5.3. Egypt

14.5.3.1.  Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.3.1.1.  Pre-Clinical 14.5.3.1.2. Phase I clinical trial 14.5.3.1.3. Others

14.5.3.2.  Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.3.2.1.  Short-term solution of renal dialysis 14.5.3.2.2. Longer-term of a living kidney transplant 14.5.3.2.3. Polycystic Kidney Disease

14.5.3.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.3.2.5. Others

14.5.3.3.  Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.3.3.1.  Hospital

14.5.3.3.2.  Organ Transplant Centers 14.5.3.3.3. Research Institutes

14.5.3.3.4. Others

14.5.4. Kuwait

14.5.4.1.  Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.4.1.1.  Pre-Clinical 14.5.4.1.2. Phase I clinical trial

14.5.4.1.3. Others

14.5.4.2.  Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.4.2.1.  Short-term solution of renal dialysis 14.5.4.2.2. Longer-term of a living kidney transplant 14.5.4.2.3. Polycystic Kidney Disease

14.5.4.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.4.2.5. Others

14.5.4.3.  Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.4.3.1.  Hospital

14.5.4.3.2.  Organ Transplant Centers 14.5.4.3.3. Research Institutes

14.5.4.3.4. Others

14.5.5. South Africa

14.5.5.1.  South Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.5.1.1.  Pre-Clinical 14.5.5.1.2. Phase I clinical trial 14.5.5.1.3. Others

14.5.5.2.  South Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.5.2.1.  Short-term solution of renal dialysis 14.5.5.2.2. Longer-term of a living kidney transplant 14.5.5.2.3. Polycystic Kidney Disease

14.5.5.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.5.2.5. Others

14.5.5.3.  South Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.5.3.1.  Hospital

14.5.5.3.2.  Organ Transplant Centers 14.5.5.3.3. Research Institutes

14.5.5.3.4. Others

14.5.6. Rest of Middle East & Africa

14.5.6.1.  Rest of Middle East & Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

14.5.6.1.1.  Pre-Clinical 14.5.6.1.2. Phase I clinical trial

14.5.6.1.3. Others

14.5.6.2.  Rest of Middle East & Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

14.5.6.2.1.  Short-term solution of renal dialysis 14.5.6.2.2. Longer-term of a living kidney transplant 14.5.6.2.3. Polycystic Kidney Disease

14.5.6.2.4. Focal Segmental Glomerulosclerosis (FSGS) 14.5.6.2.5. Others

14.5.6.3.  Rest of Middle East & Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

14.5.6.3.1.  Hospital

14.5.6.3.2.  Organ Transplant Centers 14.5.6.3.3. Research Institutes

14.5.6.3.4. Others

14.6. Key Segment for Channeling Investments

14.6.1. By Country

14.6.2. By Clinical Trial

14.6.3. By Application

14.6.4. By End User

15.  Latin America Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030

15.1. Overview

15.1.1. Latin America Bioartificial Kidney Market Revenue (US$ Mn)

15.2. Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

15.2.1. Pre-Clinical

15.2.2. Phase I clinical trial

15.2.3. Others

15.3. Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

15.3.1. Short-term solution of renal dialysis

15.3.2. Longer-term of a living kidney transplant

15.3.3. Polycystic Kidney Disease

15.3.4. Focal Segmental Glomerulosclerosis (FSGS)

15.3.5. Others

15.4. Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

15.4.1. Hospital

15.4.2. Organ Transplant Centers

15.4.3. Research Institutes

15.4.4. Others

15.5. Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country

15.5.1. Brazil

15.5.1.1.  Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

15.5.1.1.1.  Pre-Clinical 15.5.1.1.2. Phase I clinical trial 15.5.1.1.3. Others

15.5.1.2.  Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

15.5.1.2.1.  Short-term solution of renal dialysis 15.5.1.2.2. Longer-term of a living kidney transplant 15.5.1.2.3. Polycystic Kidney Disease

15.5.1.2.4. Focal Segmental Glomerulosclerosis (FSGS) 15.5.1.2.5. Others

15.5.1.3.  Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

15.5.1.3.1.  Hospital

15.5.1.3.2.  Organ Transplant Centers 15.5.1.3.3. Research Institutes

15.5.1.3.4. Others

15.5.2. Argentina

15.5.2.1.  Argentina Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

15.5.2.1.1.  Pre-Clinical 15.5.2.1.2. Phase I clinical trial 15.5.2.1.3. Others

15.5.2.2.  Argentina Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

15.5.2.2.1.  Short-term solution of renal dialysis 15.5.2.2.2. Longer-term of a living kidney transplant 15.5.2.2.3. Polycystic Kidney Disease

15.5.2.2.4. Focal Segmental Glomerulosclerosis (FSGS) 15.5.2.2.5. Others

15.5.2.3.  Argentina Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

15.5.2.3.1.  Hospital

15.5.2.3.2.  Organ Transplant Centers 15.5.2.3.3. Research Institutes

15.5.2.3.4. Others

15.5.3. Rest of Latin America

15.5.3.1.  Rest of Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial

15.5.3.1.1.  Pre-Clinical 15.5.3.1.2. Phase I clinical trial 15.5.3.1.3. Others

15.5.3.2.  Rest of Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application

15.5.3.2.1.  Short-term solution of renal dialysis 15.5.3.2.2. Longer-term of a living kidney transplant 15.5.3.2.3. Polycystic Kidney Disease

15.5.3.2.4. Focal Segmental Glomerulosclerosis (FSGS) 15.5.3.2.5. Others

15.5.3.3.  Rest of Latin America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User

15.5.3.3.1.  Hospital

15.5.3.3.2.  Organ Transplant Centers 15.5.3.3.3. Research Institutes

15.5.3.3.4. Others

15.6. Key Segment for Channeling Investments

15.6.1. By Country

15.6.2. By Clinical Trial

15.6.3. By Application

15.6.4. By End User

16.  Competitive Benchmarking

16.1. Global Presence and Growth Strategies

16.1.1. Mergers and Acquisitions

16.1.2. Product Launches

16.1.3. Investments Trends

16.1.4. R&D Initiatives

17.  Player Profiles

17.1. AWAK Technologies

17.1.1. Company Details

17.1.2. Company Overview

17.1.3. Product Offerings

17.1.4. Key Developments

17.1.5. Financial Analysis

17.1.6. SWOT Analysis

17.1.7. Business Strategies

17.2. Blood Purification Technologies Inc.

17.2.1. Company Details

17.2.2. Company Overview

17.2.3. Product Offerings

17.2.4. Key Developments

17.2.5.  Financial Analysis

17.2.6. SWOT Analysis

17.2.7. Business Strategies

17.3. Dutch Kidney Foundation

17.3.1. Company Details

17.3.2. Company Overview

17.3.3. Product Offerings

17.3.4. Key Developments

17.3.5. Financial Analysis

17.3.6. SWOT Analysis

17.3.7. Business Strategies

17.4. UCSF

17.4.1. Company Details

17.4.2. Company Overview

17.4.3. Product Offerings

17.4.4. Key Developments

17.4.5. Financial Analysis

17.4.6. SWOT Analysis

17.4.7. Business Strategies

17.5. Other Market Participants

18.  Key Findings

 

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

 

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com